Efficacy of Breast Cancer Screening in Reducing Mortality

Evidence for Mortality Reduction from Breast Cancer Screening

The American College of Radiology recommends mammography screening, which demonstrates a 40% reduction in breast cancer mortality in women who are actually screened, making it the only screening modality proven to decrease breast cancer mortality 1, 2
Mammography is the only screening modality conclusively shown to decrease breast cancer mortality, with multiple randomized controlled trials demonstrating at least a 22% reduction in breast cancer mortality 1
The Swedish Two-County trial showed a 27-31% reduction in breast cancer mortality after 29 years of follow-up in women aged 40-74 years invited to screening 1
Observational studies from population-based service screening programs demonstrate even larger mortality reductions (40%) in women who actually received screening compared to those who were only invited 1, 2
Annual screening mammography for women 40-84 years decreases mortality by 40% (12 lives per 1,000 women screened), whereas biennial screening for women 50-74 years only decreases mortality by 23% (7 lives per 1,000 women screened) 2

For women aged 40-49 years, screening demonstrates a mortality reduction of 48% (RR 0.52; 95% CI, 0.4-0.67) among those exposed to screening 3
Women aged 50-69 years show a 44% (RR 0.56; 95% CI, 0.49-0.64) reduction in mortality when exposed to screening 3
The number needed to screen (NNS) to prevent one breast cancer death varies by age group, with 726 women needing to be screened 5-6 times over 10 years for women aged 40-49 years 3
For women aged 50-51 years, 111-143 women need to be screened biennially until age 69 to prevent one breast cancer death 4

Screening reduces the risk of being diagnosed with advanced breast cancer, with a 45% reduction in tumors >2cm for women aged 40-49 years (RR 0.55; 95% CI, 0.46-0.66) 3
Screen-detected tumors are typically lower stage (smaller and more likely to be node-negative) compared to cancers detected by palpation, which decreases treatment morbidity 1

Mortality reduction is greater when screening begins at age 40 rather than 45 or 50 years, and when performed annually rather than biennially 1, 2
Digital breast tomosynthesis (DBT) has shown improved cancer detection rates and decreased recall rates compared to digital mammography 1

Approximately 10% of screening mammograms result in recall for additional imaging, although less than 2% lead to biopsy recommendations 1, 2
Overdiagnosis estimates vary widely, with adjusted estimates ranging from 1-10%, increasing with age at screening 1, 2

Women with genetic mutations or ≥20% lifetime risk should receive annual MRI starting at age 25-30 and annual mammography between ages 25-40 5

Despite varying guidelines due to different perceptions of risks and benefits, the evidence consistently supports that screening mammography saves lives 1, 4
The balance of benefits to harms is favorable, with approximately twice as many lives saved compared to cases overdiagnosed 4